治疗非全身性青少年异常性关节炎的治疗方法
Susan Shenoi1, Gerd Horneff2,3, Amita Aggarwal4
1Seattle Children's Hospital and Research Centre, University of Washington, Seattle, WA, USA.
Nature reviews. Rheumatology
|February 6, 2024
概括
青春期异常性关节炎 (JIA) 治疗已经进步,有了新的治疗方法,并专注于缓解. 本综述涵盖了管理非系统性JIA表型的当前证据,包括骨关节炎和多关节炎.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学 是一个学科.
背景情况:
- 在过去的20年里,青少年无形性关节炎 (JIA) 的治疗方法有了显著的进化.
- 新的疗法和对早期缓解的关注改善了结果.
- 合并动脉炎是异质的,需要针对不同亚型量身定制的治疗策略.
研究的目的:
- 审查目前关于非系统性JIA表型治疗方法的证据.
- 讨论对橄关节炎,多关节炎,肠炎相关关节炎和牛皮关节炎的管理策略.
- 突出既有和较新的疾病修饰性抗风湿药物 (DMARDs) 的作用.
主要方法:
- 对最近对生物和合成DMARDs进行的随机对照试验 (RCT) 的审查.
- 分析最新的治疗建议和指导方针.
- 在JIA中对治疗到目标策略的证据综合.
主要成果:
- 较新的生物和合成DMARDs丰富了JIA治疗选择.
- 像甲状腺素这样的既定药物仍然至关重要.
- 跨国指导方针支持JIA的治疗目标方法.
结论:
- 目前的JIA管理强调早期缓解和量身定制的方法.
- 需要进一步研究持续缓解的最佳治疗中止.
- 本综述提供了管理非系统性JIA表型的全面概述.
相关概念视频
Tonsillitis II: Management
111
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
111
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137


